Non-Human Primate (NHP) Applications in Cell Therapy (CAR-T, iPSC, MSC)

Are you currently facing complex clinical trial challenges, safety concerns, or long development cycles in cell therapy? Our NHP based services help you accelerate the clinical translation of your cell and gene therapies by providing critical preclinical data. Through our advanced NHP models, we enable you to obtain the essential safety, efficacy, and biodistribution data required for regulatory submissions.

Harnessing NHP Models in Cell Therapy (CAR-T, iPSC, MSC) to Speed Up Your Drug Discovery Journey!

NHP models provide essential translational data for the safety, biodistribution, and efficacy of advanced cell and gene therapies.

Get a Quote

Overview of NHP Applications in Cell Therapy

What Are Our Research Areas?

Creative Biolabs provides comprehensive preclinical research services for advanced cell therapies, including CAR-T, iPSC, and MSC-based treatments. We leverage NHP models to address critical research questions that cannot be answered by traditional preclinical species. Our capabilities span foundational research areas, providing the robust data necessary to support your program's progression toward human clinical trials.

Engraftment, Persistence & Trafficking Analysis: A critical step that involves tracking the location and survival of transplanted cells or the spread of viral vectors within the body.
Cytokine Release Syndrome (CRS) Modeling: Understanding the potential for this systemic inflammatory response that can occur with immunotherapies like CAR-T.
Delivery Route & Dose Optimization: A major focus to determine the safest and most effective way to administer a therapy, while minimizing off-target effects and potential tissue damage.

Why Choose Us?

NHPs offer a unique and irreplaceable advantage in the development of cell and gene therapies due to their close resemblance to humans. This translational relevance is critical for de-risking your program.

Genetic and Immunological Similarities: NHPs share a high degree of genetic and immunological homology with humans, leading to more predictive and clinically relevant immune response data.
Clinical Translational Relevance: Data obtained from NHP studies provides a more accurate approximation of human physiological responses, helping to bridge the gap between preclinical and clinical stages.
Regulatory Submission Data: Data generated from well-designed NHP studies are often required for regulatory submissions, such as Investigational New Drug (IND) applications with global regulatory bodies.

Fig.1 Characterization of transgene-free NHP-derived iPSCs.¹

Key Applications

NHP models are indispensable for evaluating the safety and efficacy of cell therapies in a context that closely mimics the human system. Our platform enables the following critical applications:

Vector Biodistribution and Shedding Studies for Gene Therapies: For adeno-associated virus (AAV) and lentiviral vector-based therapies, we track the precise biodistribution and shedding patterns, providing essential data on vector persistence, tropism, and off-target effects. This is crucial for verifying that the vector reaches the intended tissue and does not pose a systemic risk.
CAR-T Cell Expansion, Persistence, and Cytokine Release Syndrome (CRS) Modeling: Our models are used to monitor the in vivo expansion and persistence of CAR-T cells, as well as to model and mitigate potentially life-threatening CRS. This provides crucial insights into the therapy's safety and effectiveness before human trials.
iPSC and MSC Engraftment and Differentiation Analysis: We assess the successful engraftment and long-term differentiation of induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSCs), providing data on the cells' ability to survive, integrate, and regenerate targeted tissues.

How Do Creative Biolabs Support Your Projects?

Creative Biolabs offers a suite of services designed to accelerate your cell therapy program. Our capabilities are aligned with key stages of preclinical development.

Service Capability	Corresponding Application Area
Immunotoxicity & Cytokine Release Assays (CRAs)	We provide an in vivo platform to model and mitigate potential CRS.
PK/TK Sample Analysis	We provide Vector Copy Number (qPCR, ddPCR) analysis.
ADA/Immunogenicity Testing	We offer ADA & Neutralizing Antibody (NAb) Assays and Immune Complex Detection.
Biomarker Profiling	Identifies and characterizes host immune responses to vectors and transgenes.

Translational Impact

By leveraging our NHP models, clients gain a significant advantage in their drug development programs. NHP studies provide a more reliable early proof of concept, which can help to attract further investment and accelerate your program's timeline. Our models enable the early detection of potential immune responses and toxicity, allowing for proactive mitigation strategies. This ultimately reduces the risk of costly and time-consuming IND failures. The biodistribution, shedding, and safety data from well-conducted NHP studies are often required by regulatory bodies for gene therapy IND submissions, making this research a critical step toward clinical readiness.

Frequently Asked Questions

Q: What is the resolution and sensitivity of your in vivo imaging for cell tracking?

A: Our advanced imaging platforms provide high-resolution, high-sensitivity tracking of therapeutic cells, allowing for the precise visualization of their location, persistence, and trafficking in real-time. This provides a clear picture of biodistribution and engraftment, which is essential for understanding your therapy's mechanism.

Q: What cell sources or sample types can you work with?

A: We have extensive experience working with a wide range of cell types, including CAR-T cells, iPSCs, and MSCs, as well as various viral vectors like AAV and lentivirus. Our teams are adept at handling and administering both human-derived and NHP-derived cells, ensuring seamless integration into our study models.

Q: What is the typical turnaround time for a complete study and what data format can I expect?

A: Study timelines are project-specific and depend on the complexity of your therapy and the required endpoints. We work collaboratively to develop a detailed timeline and deliver comprehensive data packages, including raw data, finalized reports, and histopathological analysis. We provide all data in a clear, organized format that is ready for your internal review and regulatory submissions.

Q: How do NHP models provide a superior advantage compared to other preclinical models, such as rodents?

A: While rodent models are useful for initial screening, NHPs provide a more translational platform due to their anatomical, physiological, and immunological similarities to humans. This reduces the risk of unexpected outcomes in clinical trials and provides a more accurate assessment of a therapy's safety and efficacy.

Q: What safety measures do you have in place to monitor for immune responses or other adverse events?

A: Our preclinical studies are designed with robust safety monitoring protocols. We perform continuous observation, regular clinical pathology, and cytokine profiling to detect any signs of immune response or adverse events, such as CRS, early on. This proactive approach ensures the safety of the study while providing you with crucial safety data.

Contact Us

Creative Biolabs is your trusted partner for NHP-based cell therapy research. Our expertise and advanced models help you bridge the gap between preclinical discovery and clinical success. Ready to leverage our NHP platform for your next study? Contact Our Team for More Information and to Discuss Your Project

Reference

Stauske, Michael, et al. "Non-human primate iPSC generation, cultivation, and cardiac differentiation under chemically defined conditions." Cells 9.6 (2020): 1349. Distributed under Open Access license CC BY 4.0, without modification. DOI: https://doi.org/10.3390/cells9061349